Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World June 2011	Column: In the pipeline Chemists are human. Humans are hierarchical. Therefore...well, therefore, you'll find a number of different roles and levels for scientists in a drug company's labs. Here's a rough ordering, from least experienced to most.
Chemistry World October 2010	Column: In the pipeline Derek Lowe investigates the comeback combinatorial chemistry has made in the field of drug discovery
Chemistry World November 2009 Derek Lowe	Column: In the pipeline The author advises opening your mind during the screening cascade taken by potential drug targets, and remaining goal orientated at all times
Chemistry World January 2012	Column: In the pipeline Derek Lowe discusses how companies are increasingly trying to do more with the compounds they already know a lot about
Chemistry World June 2008	Column: In the pipeline The author, a medicinal chemist working on preclinical drug discovery, takes a look at the differences between chemists and biologists working on the same team.
Chemistry World September 2009	Column: In the pipeline What's the most difficult therapeutic area for drug discovery? They're certainly not all created equal - or if they were, they have definitely diverged since then. The question can be narrowed down quite a bit.
Chemistry World July 2010	Column: In the pipeline Derek Lowe ponders the possibility of phosphatase inhibitors
Chemistry World September 2007 Derek Lowe	Column: In the Pipeline Will Phase Zero trials actually help drug development?
The Motley Fool May 18, 2011 Frank Vinluan	Targacept's $75M Stock Offering Targets Cognitive Disorders R&D AstraZeneca bailed, but Targacept keeps on trucking.
Chemistry World April 2011	Molecular Obesity is Weighing Down Drug Discovery Medicinal chemistry's quest for potent drug candidates has resulted in molecules that are too large and too lipophilic for their own good.
Chemistry World June 17, 2015 James Urquhart	Promising compound offers single dose knock-out for malaria Ian Gilbert and colleagues, working with the Medicines for Malaria Venture, have found a compound dubbed DDD107498 which kills Plasmodium falciparum -- the species responsible for most dangerous form of malaria.
Chemistry World July 2009 Derek Lowe	Column: In the pipeline The author wonders where we'd be without the formulation chemists
Chemistry World July 30, 2015 Derek Lowe	A precision instrument? How much do medicinal chemists and their biology colleagues really trust each other's data? In the end, they have to, because drug discovery is a team sport.
The Motley Fool June 3, 2011 Frank Vinluan	GSK Sees Positive Results on Asthma, COPD Drug Expected to Succeed Advair GSK gets good news.
Chemistry World November 30, 2012 Andy Extance	Chemists cull compounds using 'intuition' Medicinal chemists might be using far fewer parameters to choose candidate fragments for a screening collection than they think they do. Their choices can be mimicked based on just one or two properties, a team led by researchers at Swiss-headquarted pharmaceutical firm Novartis has found.
Chemistry World June 1, 2012 Derek Lowe	Peace, love and understanding You'd think that the chemists and biologists working in drug discovery would understand each other pretty well by now. You would be wrong about that.
Chemistry World June 2010	Column: In the pipeline Derek Lowe looks into his crystal ball to see what the future of medicinal chemistry might be
The Motley Fool July 30, 2010 Brian Orelli	3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company.
Chemistry World April 14, 2011 Sarah Farley	Fish in chips: growing embryos in microfluidic systems Scientists in the Netherlands and the UK have shown for the first time that an animal embryo can develop in a microfluidic environment.
Chemistry World March 2011	Column: In the pipeline Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations
Chemistry World October 2008 Derek Lowe	Column: In the pipeline The author seeks a cure for 'compound bloat'
Chemistry World April 2011	Column: In the Pipeline If you look over the whole pharmacopeia, you'll see there are a lot of compounds that got their start as natural products.
Chemistry World July 26, 2012 Derek Lowe	Screen shots You might not think that the makeup of a compound screening collection could set off many arguments, but there are a few issues there that will do the trick almost every time.
Chemistry World September 2008 Derek Lowe	Column: In the pipeline The author remembers leaving the ivory towers of academe to trade 'unusual and beautiful' for 'useful'
Chemistry World June 2008 Sarah Houlton	Breaking the rules The author finds out about some chemical tricks that can give a new drug the best possible odds of success
Chemistry World August 2011	Column: In the pipeline Derek Lowe highlights the less visible pitfalls on the road to a new drug
Chemistry World January 2011	Column: In the pipeline Some medicinal chemists can't get enough fluorines in their molecules. The love-hate relationship is explained.
Chemistry World August 2007 Derek Lowe	Opinion: In the Pipeline Process chemists just don't get the credit they deserve.
The Motley Fool December 5, 2005 W.D. Crotty	Rigel Pharmaceuticals Gets Stomped The biotech tumbles on poor phase 2 trial results for an allergy drug. Until another compound begins to offer glimmers of hope, this stock will probably offer little if any price appreciation.
Chemistry World November 2010	Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream?
The Motley Fool March 21, 2007 Brian Lawler	New Indication for Pain Pain Therapeutics brings a new drug into the clinic. When drug companies attempt to bring new drugs that are outside of their core competencies to market, investors always need to be wary.
Chemistry World November 2008 Derek Lowe	Column: In the pipeline Drug discovery chemists live by assay data; we depend on these numbers to tell us if we're heading in the right direction with our molecules.
Pharmaceutical Executive February 1, 2006 Ron Feemster	Gene Logic: Rescue Squad One or two late-stage clinical failures can land promising drug candidates on the shelf. Forever? Maybe not. Gene Logic tests Big Pharma's dead drugs for hundreds of different targets.
Chemistry World February 2011	Column: In the pipeline Enzymes have been giving chemists inferiority complexes since day one, says Derek Lowe. But there's no denying their potential
Chemistry World July 2, 2013 Derek Lowe	Target acquired Phenotypic screening has recently seen a revival in popularity. This technique assesses drug candidates first by their effects in some organism, then works back to their causes. It can be an effective strategy, but when you find some interesting results, the need to explain them can become acute.
Chemistry World January 2012	Rising interest in compound bank David Fox argues for the creation of a centralized repository for small molecules to harness research efforts in drug discovery
Chemistry World July 2008 Kevin Rogers	What future for small molecule therapy? Pharmaceutical companies overlook bench chemists at their peril
Bio-IT World November 12, 2002 James Golden	The Business of Bioinformatics The industry has reached an interesting crossroads. As an academic branch of learning, bioinformatics remains mostly what it always was, a cross-disciplinary endeavor between computer science and molecular biology. But bioinformatics as a money-making proposition has different criteria for success.
Chemistry World January 2010 Derek Lowe	Column: In the pipeline I've recently marked my 20th year of drug discovery research, which prompted me to think about what has changed since I started work in the industry.
Bio-IT World Dec 2006/Jan 2007 Giacomo Bastianelli	The Future of Predictive Biology Predictive biology, data and the integration of disparate research disciplines are key ingredients for the future of drug discovery research and healthcare.
Chemistry World July 22, 2015 Judy Hayler	The handbook of medicinal chemistry: principles and practice The handbook of medicinal chemistry: principles and practice guides the reader through the R&D process from target validation to late stage clinical trials, via a series of chapters written by individuals in industry and academia.
Chemistry World December 2008	Column: In the pipeline I've worked on two drug discovery efforts (one right after the other, as fate would have it) whose final compounds differed by essentially one methyl group from the starting points of each project.
Chemistry World May 31, 2009 Nina Notman	The natural approach to winning at drug discovery High throughput drug screening is often described as a casino, with the odds stacked on the side of success as long as a big enough library is used.
The Motley Fool September 8, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
Chemistry World June 28, 2007 Hepeng Jia	First Internationally Licensed Chinese Herbal Patent China has licensed its first herbal compound patent to an overseas pharmaceutical company.
Chemistry World April 21, 2010 Sarah Houlton	Fresh hep C hope A new kind of compound to treat hepatitis C is showing promise in early clinical trials.
The Motley Fool May 1, 2007 Brian Lawler	Cardiome Plays Dealmaker Cardiome signs a deal to develop one of Eli Lilly's drug candidates. Investors, take note.
Chemistry World November 16, 2012 Yuandi Li	(+)-Myrrhanol C made Spanish chemists have completed the stereospecific total synthesis of (+)-myrrhanol C. This compound is a natural triterpene isolated from mastic gum, a substance well known for its medicinal properties as well as use in various cuisines.
Chemistry World March 2012	Lead-oriented synthesis Ian Churcher and Alan Nadin call for the development of more robust synthetic tools to improve small molecule survival rates in the perilous journey from lead to drug
The Motley Fool June 21, 2007 Brian Orelli	Dumpster Diving in Pfizer's Trash Investors are probably overreacting to Pfizer's decision, but only time -- and clinical trials -- will tell.